VivoSeq
Other

Endocrine Therapy

0

Pipeline Programs↗

15

Active Trials↗

0

Companies Involved↗

Endocrine Therapy is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

24

clinical trials

Active, not recruiting8 · 33%
Recruiting6 · 25%
Completed6 · 25%
Unknown status3 · 13%
Not yet recruiting1 · 4%

Clinical Trials

Trial Activity

24 trials

Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)
Recruiting·GGeorge Washington University·Phase 2·NCT06806930·90 enrolled
Vitamin D for Prostate Endocrine Therapy
Recruiting·UUniversity of Rochester·Phase 3·NCT05838716·240 enrolled
Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy
Recruiting·—·Phase 4·NCT05809024·100 enrolled
Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.
Recruiting·HHunan Cancer Hospital·N/A·NCT06033287·300 enrolled
Biomarkers to Detect Endocrine Therapy Resistance
Recruiting·UUniversity of Wisconsin, Madison·Phase 2·NCT06067503·8 enrolled
PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study
Recruiting·SSamsung Medical Center·Phase 2·NCT04819243·178 enrolled
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
Active, not recruiting·BBaylor Breast Care Center·Phase 2·NCT00999804·128 enrolled
Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)
Active, not recruiting·JJules Bordet Institute·Phase 2·NCT04551495·65 enrolled
PreOperative Endocrine Therapy for Individualised Care With Abemaciclib
Active, not recruiting·IInstitute of Cancer Research, United Kingdom·Phase 3·NCT04584853·123 enrolled
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC
Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT03439735·45 enrolled
Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy
Active, not recruiting·UUniversity of Nebraska·Phase 2·NCT05069038·51 enrolled
Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance
Active, not recruiting·OOttawa Hospital Research Institute·Phase 4·NCT05754528·240 enrolled
Palbociclib After CDK and Endocrine Therapy (PACE)
Active, not recruiting·—·Phase 2·NCT03147287·220 enrolled
Trial of Perioperative Endocrine Therapy - Individualising Care
Active, not recruiting·IInstitute of Cancer Research, United Kingdom·Phase 3·NCT02338310·4,486 enrolled
Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy
Not yet recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 1/2·NCT07189884·33 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)